Several psychiatric adverse events (eg, depression, fatigue, psychoses, behavior troubles, anxiety, irritability, deteriorated concentration, and insomnia) that are likely to occur during the treatment course with PegIntron plus Rebetol may prompt patients to discontinue their treatment early. The goal of this study is to assess whether a psychotherapy support program may contribute to a better adherence rate.
Enrollment of participants will occur in a sequential order of treatment initiation.
Study Type
OBSERVATIONAL
Enrollment
614
Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg\^kg\^week
Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day
Each site has implemented a psychotherapy support program.
Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C When Administered With a Patient Psychotherapy Support Program as Compared to a Group Without a Psychotherapy Support Program.
Time frame: 12 months after onset of treatment
the Average Length of Treatment for Participants on Treatment for Hepatitis C With PegIntron Pen/Rebetol
Time frame: 12 months after onset of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.